Phase II Trial Assessing the Repeatability and Tumor Uptake of [⁶⁸Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.

"DISCLOSURE This project was funded by Kom op tegen Kanker (Stand Up to Cancer), the Flemish Cancer Society, and by IWT TBM (IWT150198). Odrade Gondry received an Emmanuel Van der Schueren grant funded by Kom op tegen Kanker (Stand Up to Cancer), the Flemish Cancer Society. Nick Devoogdt and Tony Lahoutte are shareholders and consultants for Precirix. Nick Devoogdt, Tony Lahoutte, and Marleen Keyaerts are shareholders and consultants for Abscint NV/SA, which has licensed a patent on the diagnostic HER2-sdAb tracer described in this study. Sheeno Thyparambil works for mProbe. Catarina Xavier, Nick Devoogdt, Tony Lahoutte, and Marleen Keyaerts hold patents related to sdAb imaging and therapy. Tony Lahoutte and Marleen Keyaerts have an FWO clinical mandate. No other potential conflict of interest relevant to this article was reported."

"This project was funded by Kom op tegen Kanker (Stand Up to Cancer), the Flemish Cancer Society, and by IWT TBM (IWT150198). Odrade Gondry received an Emmanuel Van der Schueren grant funded by Kom op tegen Kanker (Stand Up to Cancer), the Flemish Cancer Society. Nick Devoogdt and Tony Lahoutte are shareholders and consultants for Precirix. Nick Devoogdt, Tony Lahoutte, and Marleen Keyaerts are shareholders and consultants for Abscint NV/SA, which has licensed a patent on the diagnostic HER2-sdAb tracer described in this study. Sheeno Thyparambil works for mProbe. Catarina Xavier, Nick Devoogdt, Tony Lahoutte, and Marleen Keyaerts hold patents related to sdAb imaging and therapy. Tony Lahoutte and Marleen Keyaerts have an FWO clinical mandate. No other potential conflict of interest relevant to this article was reported."